Homburger advised Vifor Pharma
Vifor Pharma and Angion Biomedica Corp. announced the signing of a licensing agreement for the commercialization of Angion’s ANG-3777 molecule developed for treatment of delayed graft function (DGF) and cardiac surgery-associated acute kidney injury (CSA-AKI). Under the terms of the agreement, Vifor Pharma has been granted an exclusive license for commercializing ANG-3777 nephrology indications worldwide except Greater China. Further, Vifor Pharma has, apart from upfront, clinical and commercial milestone payments as well as royalty payments, agreed to a considerable equity investment in Angion.
